ImmunoPrecise Antibodies Ltd (IPA) concluded trading on Wednesday at a closing price of $0.36, with 45.85 million shares of worth about $16.51 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -55.90% during that period and on Wednesday the price saw a loss of about -3.95%. Currently the company’s common shares owned by public are about 30.29M shares, out of which, 20.05M shares are available for trading.
Stock saw a price change of -16.93% in past 5 days and over the past one month there was a price change of -33.85%. Year-to-date (YTD), IPA shares are showing a performance of -13.24% which decreased to -81.20% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.32 but also hit the highest price of $2.43 during that period. The average intraday trading volume for ImmunoPrecise Antibodies Ltd shares is 6.33 million. The stock is currently trading -18.85% below its 20-day simple moving average (SMA20), while that difference is down -23.21% for SMA50 and it goes to -47.69% lower than SMA200.
ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) currently have 30.29M outstanding shares and institutions hold larger chunk of about 7.75% of that.
The stock has a current market capitalization of $16.35M and its 3Y-monthly beta is at 0.38. It has posted earnings per share of -$0.75 in the same period. It has Quick Ratio of 0.85 while making debt-to-equity ratio of 0.50. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IPA, volatility over the week remained 18.57% while standing at 12.26% over the month.
Stock’s fiscal year EPS is expected to rise by 63.48% while it is estimated to increase by 53.41% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on December 02, 2022 offering a Buy rating for the stock and assigned a target price of $9 to it. Coverage by The Benchmark Company stated ImmunoPrecise Antibodies Ltd (IPA) stock as a Buy in their note to investors on October 25, 2021, suggesting a price target of $12 for the stock.
